|
|
|
|
Vol. 60, Issue 3, 568-576, September 2001
3
4 Nicotinic Acetylcholine
Receptors Stably Expressed in Human Embryonic Kidney 293 Cells
Department of Pharmacology, Georgetown University School of
Medicine, Washington, DC
Effects of agonists on rat
3
4 nicotinic acetylcholine receptors
expressed in KX
3
4R2 cells [human embryonic kidney
293-derived cells] were studied. The potencies of seven agonists
varied over a 7000-fold range, with a rank order of epibatidine
A85380 > cytisine
1,1-dimethyl-4-phenyl-piperazinium
iodide (DMPP)
nicotine > acetylcholine > carbachol. The efficacies of all of the agonists studied here were
similar except for DMPP, which seemed to be a partial agonist compared
with nicotine and acetylcholine. Nicotine and carbachol desensitized
the receptors in a time- and concentration-dependent manner. The
EC50 values for nicotine and carbachol to desensitize the
receptors during a 60-min exposure were 3 and 51 µM, respectively,
indicating that these agonists are more potent at desensitizing the
receptors than at activating them. The function of the receptors
recovered from agonist-induced desensitization rapidly and almost
completely. The half-time for recovery of function from desensitization
after a 60-min treatment with nicotine increased with the concentration
of nicotine used to desensitize the receptors. In contrast, no such
concentration dependence for time to recovery of function was found
when carbachol was used to desensitize the receptors. We propose that
this difference may be due to the cell permeability of nicotine,
allowing it to enter and be sequestered inside of cells and then slowly
diffuse out to maintain receptor desensitization. After a 5-day
exposure to 100 µM nicotine, the receptors were completely
desensitized, but receptor function recovered to 83% of control values
with a half-time of about 10.5 min. Although the number of nicotinic receptor binding sites measured with
(±)-[3H]epibatidine was increased during the
chronic treatment with nicotine, no increase in function was detected.
This article has been cited by other articles:
![]() |
M. Ohtani, T. Oka, M. Badyuk, Y. Xiao, K. J. Kellar, and J. W. Daly Mouse beta-TC6 Insulinoma Cells: High Expression of Functional {alpha}3beta4 Nicotinic Receptors Mediating Membrane Potential, Intracellular Calcium, and Insulin Release Mol. Pharmacol., March 1, 2006; 69(3): 899 - 907. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Beckel, A. Kanai, S.-J. Lee, W. C. de Groat, and L. A. Birder Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells Am J Physiol Renal Physiol, January 1, 2006; 290(1): F103 - F110. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kuryatov, J. Luo, J. Cooper, and J. Lindstrom Nicotine Acts as a Pharmacological Chaperone to Up-Regulate Human {alpha}4{beta}2 Acetylcholine Receptors Mol. Pharmacol., December 1, 2005; 68(6): 1839 - 1851. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Free, S. B. McKay, P. D. Gottlieb, R. T. Boyd, and D. B. McKay Expression of Native {alpha}3{beta}4* Neuronal Nicotinic Receptors: Binding and Functional Studies Investigating Turnover of Surface and Intracellular Receptor Populations Mol. Pharmacol., June 1, 2005; 67(6): 2040 - 2048. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alkondon and E. X. Albuquerque Nicotinic Receptor Subtypes in Rat Hippocampal Slices Are Differentially Sensitive to Desensitization and Early in Vivo Functional Up-Regulation by Nicotine and to Block by Bupropion J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 740 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Rau, R. D. Johnson, and B. Y. Cooper Nicotinic AChR in Subclassified Capsaicin-Sensitive and -Insensitive Nociceptors of the Rat DRG J Neurophysiol, March 1, 2005; 93(3): 1358 - 1371. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Hernandez, S. Vicini, Y. Xiao, M. I. Davila-Garcia, R. P. Yasuda, B. B. Wolfe, and K. J. Kellar The Nicotinic Receptor in the Rat Pineal Gland Is an {alpha}3{beta}4 Subtype Mol. Pharmacol., October 1, 2004; 66(4): 978 - 987. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xiao and K. J. Kellar The Comparative Pharmacology and Up-Regulation of Rat Neuronal Nicotinic Receptor Subtype Binding Sites Stably Expressed in Transfected Mammalian Cells J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 98 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Parker, Y. Fu, K. McAllen, J. Luo, J. M. McIntosh, J. M. Lindstrom, and B. M. Sharp Up-Regulation of Brain Nicotinic Acetylcholine Receptors in the Rat during Long-Term Self-Administration of Nicotine: Disproportionate Increase of the {alpha}6 Subunit Mol. Pharmacol., March 1, 2004; 65(3): 611 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. N. Nguyen, B. A. Rasmussen, and D. C. Perry Subtype-Selective Up-Regulation by Chronic Nicotine of High-Affinity Nicotinic Receptors in Rat Brain Demonstrated by Receptor Autoradiography J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1090 - 1097. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Boorman, M. Beato, P. J. Groot-Kormelink, S. D. Broadbent, and L. G. Sivilotti The Effects of {beta}3 Subunit Incorporation on the Pharmacology and Single Channel Properties of Oocyte-expressed Human {alpha}3{beta}4 Neuronal Nicotinic Receptors J. Biol. Chem., November 7, 2003; 278(45): 44033 - 44040. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Avila, M. I. Davila-Garcia, V. S. Ascarrunz, Y. Xiao, and K. J. Kellar Differential Regulation of Nicotinic Acetylcholine Receptors in PC12 Cells by Nicotine and Nerve Growth Factor Mol. Pharmacol., October 1, 2003; 64(4): 974 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Fitch, Y. Xiao, K. J. Kellar, and J. W. Daly Membrane potential fluorescence: A rapid and highly sensitive assay for nicotinic receptor channel function PNAS, April 15, 2003; 100(8): 4909 - 4914. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Abdrakhmanova, J. Dorfman, Y. Xiao, and M. Morad Protons Enhance the Gating Kinetics of the alpha 3/beta 4 Neuronal Nicotinic Acetylcholine Receptor by Increasing Its Apparent Affinity to Agonists Mol. Pharmacol., February 1, 2002; 61(2): 369 - 378. [Abstract] [Full Text] [PDF] |
||||